Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 62

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 62
---
, market capitalization and headcount, as well as companies with which we compete for talented executives. The compensation & people committee also annually reviews the executive pay practices of other similarly situated companies as reported by Aon through industry surveys and proxy analyses specific to the biopharmaceutical and biotechnology sectors. The compensation & people committee considers this information when making determinations for each element of compensation. In developing the peer group of companies to inform 2024 compensation decisions, our compensation & people committee, with the assistance of Aon, established a peer group of 14 publicly traded, national and regional companies in the biopharmaceutical industry based on a balance of the following criteria:

| • |     | companies with approximately 125 to 1,200 employees, a market capitalization between $500 million and $4.5 billion, a late-stage clinical or early commercial-stage portfolio with a focus on rare diseases, and annual revenue of less than $500 million; |

| • |     | companies against which we believe we compete for executive talent; and |

| • |     | public companies based in the United States whose compensation and financial data are available in proxy statements or other public documents. |

45

Based on these criteria, our peer group for 2024 was comprised of the following 14 companies:

| ACADIA Pharmaceuticals Inc.     |     | Crinetics Pharmaceuticals, Inc. |     | Sage Therapeutics, Inc.        |
| Amicus Therapeutics, Inc.       |     | Insmed Incorporated             |     | SpringWorks Therapeutics, Inc. |
| Apellis Pharmaceuticals, Inc.   |     | Mirati Therapeutics, Inc.       |     | Travere Therapeutics, Inc.     |
| Biocryst Pharmaceuticals, Inc.  |     | Mirum Pharmaceuticals, Inc.     |     | Ultragenyx Pharmaceutical Inc. |
| Blueprint Medicines Corporation |     | Rhythm Pharmaceuticals, Inc.    |     |                                |

The compensation & people committee believes the compensation practices of our peer group provide us with appropriate compensation benchmarks for evaluating the compensation of our NEOs. Notwithstanding the similarities of the peer group to our company, due to the nature of our business, we compete for executive talent with many companies that are larger and more established than we are or that possess greater resources than we do, as well as with prestigious academic and non-profitinstitutions. Other considerations, including market factors, the experience level of the executive and the executive’s performance against established corporate goals and individual objectives